Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 237-246

  LeClerc, J M ^a   Billett, A L ^a   Gelber, R D ^a   Dalton, V ^a   Tarbell, N ^a   Lipton, J M ^a   Barr, R ^a   Clavell, L A ^a   Asselin, B ^a   Hurwitz, C ^a   Schorin, M ^a   Lipshultz, S E ^a   Declerck, L ^a   Silverman, L B ^a   Cohen, H J ^a   Sallan, S E ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; CYTARABINE; DOXORUBICIN; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SKULL IRRADIATION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SALVAGE THERAPY; SURVIVAL RATE;

EID: 0036138779     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.1.237     Document Type: Article

References (30)

1. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995)
2. Improved outcome for children with acute lymphoblastic leukemia. Results of Dana-Farber Consortium Protocol 91-01
3. Long-term results of total therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St. Jude Children's Research Hospital
4. Long-term results of treatment studies for childhood acute lymphoblastic leukemia. Pediatric Oncology Group studies from 1986-1994
5. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995
6. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981-1995
7. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia
8. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia
9. Low-dose versus high-dose methotrexate during remission induction in childhood acute lympbobbstic leukemia (Protocol 81-01 update)
10. Treatment of childhood acute lymphoblastic leukemia. Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01
11. Long-term follow-up and infectious complications of therapy for acute lymphoblastic leukemia in children
12. Comparative pharmacokinetic studies of three asparaginase preparations
13. Intensified therapy for infants with acute lymphoblastic leukemia. Results from the Dana-Farber Cancer Institute Consortium
14. Nonparametric estimation from incomplete observations
15. Evaluation of survival data and two new rank order statistics arising in its consideration
16. Regression models and life-tables
17. A class of k-sample tests for comparing the cumulative incidence of competing risks
18. Induction failure in acute lymphoblastic leukemia of childhood
19. Uniform criteria for childhood acute lymphoblastic leukemia risk classification
20. Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia. Cranial radiation requires an accomplice
21. Second malignancies in patients treated for childhood acute lymphoblastic leukemia
22. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia
23. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer
24. Asparaginaseassociated lipid abnormalities in children with acute lymphoblastic leukemia
25. Bony morbidity in children treated for acute lymphoblastic leukemia
26. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone
27. Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 Gray cranial radiation therapy for high risk acute lymphoblastic leukemia. A seven-year follow-up study of the Dana-Farber Cancer Institute ALL Consortium Protocol 87-01
28. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia. Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy. A Children's Cancer Group report
29. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group Study